---
schema_version: "secwatch.filing_event.v1"
accession: "0001906324-25-000031"
form_type: "8-K"
ticker: "QDEL"
cik: "0001906324"
company_name: "QuidelOrtho Corp"
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T23:02:31.874997+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# QuidelOrtho Q4 GAAP loss $2.28/sh; FY2024 rev $2.78B; guides FY25 rev $2.60-$2.81B, adj EBITDA margin 22%

## Summary
- Q4 GAAP diluted loss per share $2.28 vs EPS $0.10 prior year; adjusted EPS $0.63 vs $1.17.
- Q4 revenue $708M, down 5% YoY; non-respiratory flat; Labs revenue grew 4% ex-COVID and non-core.
- Full-year GAAP net loss $2.03B includes $1.82B goodwill impairment; adjusted EBITDA $543M, margin 19.5%.
- FY2025 guidance: revenue $2.60-$2.81B, adjusted EBITDA $575-$615M, adjusted diluted EPS $2.07-$2.57.
- Company cites cost-savings initiatives targeting incremental margin improvement and 22% adjusted EBITDA margin in 2025.

## SEC filing metadata
- accession: 0001906324-25-000031
- form_type: 8-K
- ticker: QDEL
- cik: 0001906324
- company_name: QuidelOrtho Corp
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1906324/000190632425000031/0001906324-25-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1906324/000190632425000031/qdel-20250212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001906324-25-000031
- JSON: https://secwatch.observer/filing/0001906324-25-000031.json
- Plain text: https://secwatch.observer/filing/0001906324-25-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.